238 related articles for article (PubMed ID: 33575322)
1. The Characteristics of Natural Killer Cells in Chronic Hepatitis B Patients Who Received PEGylated-Interferon versus Entecavir Therapy.
Cao W; Li M; Zhang L; Lu Y; Wu S; Shen G; Chang M; Liu R; Gao Y; Hao H; Hu L; Yi W; Pan CQ; Xie Y
Biomed Res Int; 2021; 2021():2178143. PubMed ID: 33575322
[TBL] [Abstract][Full Text] [Related]
2. Functional molecular expression of nature killer cells correlated to HBsAg clearance in HBeAg-positive chronic hepatitis B patients during PEG-IFN α-2a therapy.
Cao W; Lu H; Zhang L; Wang S; Deng W; Jiang T; Lin Y; Yang L; Bi X; Lu Y; Zhang L; Shen G; Liu R; Chang M; Wu S; Gao Y; Hao H; Xu M; Chen X; Hu L; Xie Y; Li M
Front Immunol; 2022; 13():1067362. PubMed ID: 36479104
[TBL] [Abstract][Full Text] [Related]
3. CD56
Shi A; Zhang X; Xiao F; Zhu L; Yan W; Han M; Luo X; Chen T; Ning Q
J Viral Hepat; 2018 Nov; 25(11):1352-1362. PubMed ID: 29888839
[TBL] [Abstract][Full Text] [Related]
4. Natural Killer Cell Characteristics in Patients With Chronic Hepatitis B Virus (HBV) Infection Are Associated With HBV Surface Antigen Clearance After Combination Treatment With Pegylated Interferon Alfa-2a and Adefovir.
Stelma F; de Niet A; Tempelmans Plat-Sinnige MJ; Jansen L; Takkenberg RB; Reesink HW; Kootstra NA; van Leeuwen EM
J Infect Dis; 2015 Oct; 212(7):1042-51. PubMed ID: 25791117
[TBL] [Abstract][Full Text] [Related]
5. Upregulation of NKG2C+ natural killer cells, TLR-2 expression on monocytes and downregulation of regulatory T-cells influence PEG-IFN treatment efficacy in entecavir-suppressed patients with CHB.
Yan W; Wu D; Wang X; Chen T; Lai Q; Zheng Q; Jiang J; Hou J; Han M; Ning Q
Antivir Ther; 2015; 20(6):591-602. PubMed ID: 25814467
[TBL] [Abstract][Full Text] [Related]
6. Differential boosting of innate and adaptive antiviral responses during pegylated-interferon-alpha therapy of chronic hepatitis B.
Micco L; Peppa D; Loggi E; Schurich A; Jefferson L; Cursaro C; Panno AM; Bernardi M; Brander C; Bihl F; Andreone P; Maini MK
J Hepatol; 2013 Feb; 58(2):225-33. PubMed ID: 23046671
[TBL] [Abstract][Full Text] [Related]
7. Changes of natural killer cells' phenotype in patients with chronic hepatitis B in intermittent interferon therapy.
Bi X; Xie S; Wu S; Cao W; Lin Y; Yang L; Jiang T; Deng W; Wang S; Liu R; Gao Y; Shen G; Chang M; Hao H; Xu M; Chen X; Hu L; Lu Y; Zhang L; Xie Y; Li M
Front Immunol; 2023; 14():1116689. PubMed ID: 36793722
[TBL] [Abstract][Full Text] [Related]
8. Sequential therapy with entecavir and pegylated interferon in a cohort of young patients affected by chronic hepatitis B.
Boglione L; Cariti G; Di Perri G; D'Avolio A
J Med Virol; 2016 Nov; 88(11):1953-9. PubMed ID: 27017932
[TBL] [Abstract][Full Text] [Related]
9. CD56(+dim) and CD56(+bright) cell activation and apoptosis in hepatitis C virus infection.
Lin AW; Gonzalez SA; Cunningham-Rundles S; Dorante G; Marshall S; Tignor A; Ha C; Jacobson IM; Talal AH
Clin Exp Immunol; 2004 Aug; 137(2):408-16. PubMed ID: 15270860
[TBL] [Abstract][Full Text] [Related]
10. Downregulation and altered function of natural killer cells in hepatitis B virus patients treated with entecavir.
Zhao PW; Jia FY; Shan YX; Ji HF; Feng JY; Niu JQ; Ayana DA; Jiang YF
Clin Exp Pharmacol Physiol; 2013 Mar; 40(3):190-6. PubMed ID: 23278368
[TBL] [Abstract][Full Text] [Related]
11. [Efficacy of 104-week sequential therapy with telbivudine or entecavir in HBeAg-positive chronic hepatitis B patients with suboptimal responses to 24-week therapy with pegylated interferon-α-2a].
Luo XD; Chen XP; Chen R; Chen XF; Huang J
Zhonghua Gan Zang Bing Za Zhi; 2016 Apr; 24(4):241-5. PubMed ID: 27470620
[TBL] [Abstract][Full Text] [Related]
12. Effect of Antiviral Therapy During Pregnancy on Natural Killer Cells in Pregnant Women With Chronic HBV Infection.
Wang F; Xie S; Ran C; Hao H; Jiang T; Deng W; Bi X; Lin Y; Yang L; Sun F; Zeng Z; Xie Y; Li M; Yi W
Front Immunol; 2022; 13():893628. PubMed ID: 35677040
[TBL] [Abstract][Full Text] [Related]
13. Comparison of fibrosis regression of entecavir alone or combined with pegylated interferon alpha2a in patients with chronic hepatitis B.
Chen S; Zhou J; Wu X; Meng T; Wang B; Liu H; Wang T; Zhao X; Kong Y; Wu S; Ou X; Jia J; Sun Y; You H
Hepatol Int; 2021 Jun; 15(3):611-620. PubMed ID: 33677771
[TBL] [Abstract][Full Text] [Related]
14. Sequential combination therapy with pegylated interferon leads to loss of hepatitis B surface antigen and hepatitis B e antigen (HBeAg) seroconversion in HBeAg-positive chronic hepatitis B patients receiving long-term entecavir treatment.
Li GJ; Yu YQ; Chen SL; Fan P; Shao LY; Chen JZ; Li CS; Yi B; Chen WC; Xie SY; Mao XN; Zou HH; Zhang WH
Antimicrob Agents Chemother; 2015 Jul; 59(7):4121-8. PubMed ID: 25941216
[TBL] [Abstract][Full Text] [Related]
15. Pegylated Interferon α-2a Triggers NK-Cell Functionality and Specific T-Cell Responses in Patients with Chronic HBV Infection without HBsAg Seroconversion.
Bruder Costa J; Dufeu-Duchesne T; Leroy V; Bertucci I; Bouvier-Alias M; Pouget N; Brevot-Lutton O; Bourliere M; Zoulim F; Plumas J; Aspord C;
PLoS One; 2016; 11(6):e0158297. PubMed ID: 27348813
[TBL] [Abstract][Full Text] [Related]
16. Pegylated interferon results in higher serological, but not virological, response rates when compared to continuous entecavir.
Sonneveld MJ; Zoutendijk R; Hansen BE; Janssen HL
Antivir Ther; 2012; 17(8):1605-8. PubMed ID: 22898565
[TBL] [Abstract][Full Text] [Related]
17. A randomized, open-label clinical study of combined pegylated interferon Alfa-2a (40KD) and entecavir treatment for hepatitis B "e" antigen-positive chronic hepatitis B.
Xie Q; Zhou H; Bai X; Wu S; Chen JJ; Sheng J; Xie Y; Chen C; Chan HL; Zhao M
Clin Infect Dis; 2014 Dec; 59(12):1714-23. PubMed ID: 25190434
[TBL] [Abstract][Full Text] [Related]
18. Functional restoration of CD56
Chen T; Zhu L; Shi A; Ding L; Zhang X; Tan Z; Guo W; Yan W; Han M; Jia J; Luo X; Schuppan D; Ning Q
Hepatol Int; 2017 Sep; 11(5):419-428. PubMed ID: 28639033
[TBL] [Abstract][Full Text] [Related]
19. Treatment of pegylated interferon-α2a in chronic hepatitis B patients demonstrating a spontaneous decline in HBV DNA after acute exacerbation.
Cai Q; Chen F; Shao X; Zhang X; Zhao Z; Gao Z
Antivir Ther; 2015; 20(2):217-24. PubMed ID: 25138110
[TBL] [Abstract][Full Text] [Related]
20. Ribavirin improves the IFN-γ response of natural killer cells to IFN-based therapy of hepatitis C virus infection.
Werner JM; Serti E; Chepa-Lotrea X; Stoltzfus J; Ahlenstiel G; Noureddin M; Feld JJ; Liang TJ; Rotman Y; Rehermann B
Hepatology; 2014 Oct; 60(4):1160-9. PubMed ID: 24700342
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
